JP2014198050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014198050A5 JP2014198050A5 JP2014131072A JP2014131072A JP2014198050A5 JP 2014198050 A5 JP2014198050 A5 JP 2014198050A5 JP 2014131072 A JP2014131072 A JP 2014131072A JP 2014131072 A JP2014131072 A JP 2014131072A JP 2014198050 A5 JP2014198050 A5 JP 2014198050A5
- Authority
- JP
- Japan
- Prior art keywords
- urp
- amino acids
- protein
- module
- serine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 32
- 235000001014 amino acid Nutrition 0.000 claims 30
- 235000018102 proteins Nutrition 0.000 claims 29
- 102000004169 proteins and genes Human genes 0.000 claims 29
- 108090000623 proteins and genes Proteins 0.000 claims 29
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 18
- 238000000034 method Methods 0.000 claims 14
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 11
- 235000013922 glutamic acid Nutrition 0.000 claims 11
- 239000004220 glutamic acid Substances 0.000 claims 11
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 10
- 239000004471 Glycine Substances 0.000 claims 9
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 8
- 239000004473 Threonine Substances 0.000 claims 8
- 235000004279 alanine Nutrition 0.000 claims 8
- 235000003704 aspartic acid Nutrition 0.000 claims 8
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 8
- 229920000642 polymer Polymers 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 5
- 239000012636 effector Substances 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- -1 axoquin Proteins 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 229960003318 alteplase Drugs 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 238000010348 incorporation Methods 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 102000004452 Arginase Human genes 0.000 claims 1
- 108700024123 Arginases Proteins 0.000 claims 1
- 108010024976 Asparaginase Proteins 0.000 claims 1
- 102000015790 Asparaginase Human genes 0.000 claims 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 101001030612 Canis lupus familiaris Submaxillary mucin Proteins 0.000 claims 1
- 102100022641 Coagulation factor IX Human genes 0.000 claims 1
- 102100023804 Coagulation factor VII Human genes 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000016911 Deoxyribonucleases Human genes 0.000 claims 1
- 108010053770 Deoxyribonucleases Proteins 0.000 claims 1
- 108010057987 Desmodus rotundus salivary plasminogen activator alpha 1 Proteins 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 108010076282 Factor IX Proteins 0.000 claims 1
- 108010023321 Factor VII Proteins 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 108010014173 Factor X Proteins 0.000 claims 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 claims 1
- 102000051325 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- 102000004547 Glucosylceramidase Human genes 0.000 claims 1
- 108010017544 Glucosylceramidase Proteins 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims 1
- 102000007625 Hirudins Human genes 0.000 claims 1
- 108010007267 Hirudins Proteins 0.000 claims 1
- 108010000521 Human Growth Hormone Proteins 0.000 claims 1
- 102000002265 Human Growth Hormone Human genes 0.000 claims 1
- 239000000854 Human Growth Hormone Substances 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 108010043135 L-methionine gamma-lyase Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 102000011931 Nucleoproteins Human genes 0.000 claims 1
- 108010061100 Nucleoproteins Proteins 0.000 claims 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims 1
- 102000006382 Ribonucleases Human genes 0.000 claims 1
- 108010083644 Ribonucleases Proteins 0.000 claims 1
- 102100022831 Somatoliberin Human genes 0.000 claims 1
- 101710142969 Somatoliberin Proteins 0.000 claims 1
- 108010049264 Teriparatide Proteins 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 102000011923 Thyrotropin Human genes 0.000 claims 1
- 108010061174 Thyrotropin Proteins 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 108010092464 Urate Oxidase Proteins 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 229960003272 asparaginase Drugs 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 108010055222 clotting enzyme Proteins 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 150000001945 cysteines Chemical class 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 229950001282 desmoteplase Drugs 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 229960004222 factor ix Drugs 0.000 claims 1
- 229940012413 factor vii Drugs 0.000 claims 1
- 229960000301 factor viii Drugs 0.000 claims 1
- 229940012426 factor x Drugs 0.000 claims 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
- 229960004666 glucagon Drugs 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims 1
- 229940006607 hirudin Drugs 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229960002486 laronidase Drugs 0.000 claims 1
- 229960001267 nesiritide Drugs 0.000 claims 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 229960000424 rasburicase Drugs 0.000 claims 1
- 108010084837 rasburicase Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 claims 1
- 108700031632 somatrem Proteins 0.000 claims 1
- 229960004532 somatropin Drugs 0.000 claims 1
- 229960005460 teriparatide Drugs 0.000 claims 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74341006P | 2006-03-06 | 2006-03-06 | |
| US60/743,410 | 2006-03-06 | ||
| US74362206P | 2006-03-21 | 2006-03-21 | |
| US60/743,622 | 2006-03-21 | ||
| US11/528,950 US20070212703A1 (en) | 2005-09-27 | 2006-09-27 | Proteinaceous pharmaceuticals and uses thereof |
| US11/528,927 | 2006-09-27 | ||
| US11/528,927 US20070191272A1 (en) | 2005-09-27 | 2006-09-27 | Proteinaceous pharmaceuticals and uses thereof |
| US11/528,950 | 2006-09-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013018187A Division JP2013081481A (ja) | 2006-03-06 | 2013-02-01 | 非構造組換えポリマーおよびその使用 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014203626A Division JP2015006202A (ja) | 2006-03-06 | 2014-10-02 | 非構造組換えポリマーおよびその使用 |
| JP2016149290A Division JP2016185990A (ja) | 2006-03-06 | 2016-07-29 | 非構造組換えポリマーおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014198050A JP2014198050A (ja) | 2014-10-23 |
| JP2014198050A5 true JP2014198050A5 (enExample) | 2014-12-04 |
| JP6175030B2 JP6175030B2 (ja) | 2017-08-02 |
Family
ID=48527357
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013018187A Withdrawn JP2013081481A (ja) | 2006-03-06 | 2013-02-01 | 非構造組換えポリマーおよびその使用 |
| JP2014131072A Active JP6175030B2 (ja) | 2006-03-06 | 2014-06-26 | 非構造組換えポリマーおよびその使用 |
| JP2014203626A Pending JP2015006202A (ja) | 2006-03-06 | 2014-10-02 | 非構造組換えポリマーおよびその使用 |
| JP2016149290A Pending JP2016185990A (ja) | 2006-03-06 | 2016-07-29 | 非構造組換えポリマーおよびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013018187A Withdrawn JP2013081481A (ja) | 2006-03-06 | 2013-02-01 | 非構造組換えポリマーおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014203626A Pending JP2015006202A (ja) | 2006-03-06 | 2014-10-02 | 非構造組換えポリマーおよびその使用 |
| JP2016149290A Pending JP2016185990A (ja) | 2006-03-06 | 2016-07-29 | 非構造組換えポリマーおよびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2402754B2 (enExample) |
| JP (4) | JP2013081481A (enExample) |
| CN (1) | CN103360471B (enExample) |
| DK (1) | DK1996220T4 (enExample) |
| ES (2) | ES2529315T5 (enExample) |
| FI (2) | FI2402754T4 (enExample) |
| HK (1) | HK1203624A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102947324A (zh) | 2010-01-29 | 2013-02-27 | 阿切尔丹尼尔斯密德兰公司 | 结合有工业意义的小分子的肽结构域 |
| JP6246128B2 (ja) * | 2012-09-14 | 2017-12-13 | 公益財団法人がん研究会 | ＥｐＣＡＭに結合するペプチド |
| US9448232B2 (en) * | 2013-01-24 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Methods and materials for detecting C9ORF72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or C9ORF72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis |
| CN105985444B (zh) * | 2015-02-05 | 2024-02-13 | 博生吉安科细胞技术有限公司 | 一种嵌合抗原受体、以及快速构建嵌合抗原受体的方法及应用 |
| WO2016146174A1 (en) * | 2015-03-17 | 2016-09-22 | Biontech Ag | Compositions and methods for diagnosis and treatment of cancer |
| IT201700122135A1 (it) * | 2017-10-26 | 2019-04-26 | Jointherapeutics S R L | Acido ialuronico funzionalizzato o suo derivato nel trattamento di stati infiammatori |
| CN108931513B (zh) * | 2018-08-28 | 2021-11-19 | 河南省医药科学研究院 | 体外检测MUSK-Ab和LRP4-Ab的方法及试剂盒 |
| PL3715367T3 (pl) | 2018-09-17 | 2024-09-02 | Gi Innovation, Inc. | Białko fuzyjne zawierające białko il-2 i białko cd80 oraz jego zastosowanie |
| IL283384B2 (en) | 2018-11-27 | 2025-07-01 | Khona Scient Inc | Bidirectional multi-enzymatic scaffolds for cannabinoid biosynthesis |
| CN111948404B (zh) * | 2020-08-03 | 2023-04-07 | 融智生物科技（青岛）有限公司 | 用于筛查地中海贫血的特征蛋白标记组合物、质谱模型及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6225449B1 (en) † | 1991-10-04 | 2001-05-01 | Washington University | Hormone analogs with multiple CTP extensions |
| US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US20030049689A1 (en) * | 2000-12-14 | 2003-03-13 | Cynthia Edwards | Multifunctional polypeptides |
| PE20020908A1 (es) † | 2001-03-21 | 2002-10-26 | Cell Therapeutics Inc | Produccion recombinante de polimeros polianionicos y uso de de los mismos |
| US7081446B2 (en) † | 2002-01-31 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Long-acting follicle stimulating hormone analogues and uses thereof |
| CA2524707A1 (en) † | 2003-05-14 | 2004-12-02 | Dow Corning Corporation | Repeat sequence protein polymer active agent conjugates, methods and uses |
| NZ556726A (en) † | 2005-01-25 | 2011-04-29 | Cell Therapeutics Inc | Conjugates of biologically active proteins having a modified in vivo half-life |
| US7855279B2 (en) † | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| JP2009525946A (ja) † | 2005-12-20 | 2009-07-16 | デューク・ユニヴァーシティ | 増強された薬理学的性質を有する活性物質を送達するための方法および組成物 |
| WO2008049711A1 (en) † | 2006-10-27 | 2008-05-02 | Novo Nordisk A/S | Peptide extended insulins |
-
2007
- 2007-03-06 EP EP11172812.7A patent/EP2402754B2/en active Active
- 2007-03-06 FI FIEP11172812.7T patent/FI2402754T4/fi active
- 2007-03-06 DK DK07752636.6T patent/DK1996220T4/da active
- 2007-03-06 FI FIEP07752636.6T patent/FI1996220T4/fi active
- 2007-03-06 ES ES11172812T patent/ES2529315T5/es active Active
- 2007-03-06 CN CN201310248277.1A patent/CN103360471B/zh active Active
- 2007-03-06 ES ES07752636T patent/ES2417153T5/es active Active
-
2013
- 2013-02-01 JP JP2013018187A patent/JP2013081481A/ja not_active Withdrawn
-
2014
- 2014-06-26 JP JP2014131072A patent/JP6175030B2/ja active Active
- 2014-10-02 JP JP2014203626A patent/JP2015006202A/ja active Pending
-
2015
- 2015-04-29 HK HK15104173.4A patent/HK1203624A1/en unknown
-
2016
- 2016-07-29 JP JP2016149290A patent/JP2016185990A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6941664B2 (ja) | 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体 | |
| JP2017018125A5 (enExample) | ||
| FI2402754T4 (fi) | Ei-kiinteärakenteisia rekombinantteja polymeerejä ja niiden käyttötapoja | |
| US9714281B2 (en) | Fibronectin based scaffold domain proteins that bind IL-23 | |
| JP2019122392A5 (enExample) | ||
| JP2021501581A5 (enExample) | ||
| EP4467650A3 (en) | Scaffold proteins | |
| MX2019015502A (es) | L-asparaginasa modificada. | |
| JP2012520085A5 (enExample) | ||
| JP2018537087A5 (enExample) | ||
| HRP20130194T1 (hr) | Imunosupresivni polipeptidi i nukleinske kiseline | |
| JP2022522650A5 (enExample) | ||
| JP2019500414A5 (enExample) | ||
| JP2020520252A (ja) | トランスジェニックマクロファージ、キメラ抗原受容体、及び関連する方法 | |
| JP2022506990A5 (enExample) | ||
| JP2016508143A5 (enExample) | ||
| JP2018524019A5 (enExample) | ||
| JP2017529868A5 (enExample) | ||
| RU2017104284A (ru) | Выделенные полипептиды cd44 и их применение | |
| JP2019518713A5 (enExample) | ||
| CN102775502A (zh) | α干扰素融合蛋白 | |
| WO2016161983A1 (zh) | 一种融合载体蛋白及其在促进目的蛋白或多肽表达中的应用 | |
| WO2019152418A3 (en) | Anti-inflammatory compounds and methods of use | |
| JP2022513379A5 (enExample) | ||
| WO2021234676A4 (en) | Compounds and methods for suppressing an immune response to substances containing polyethylene glycol |